-
Featured
Developing Tools for Active Surveillance Programs for Early-Stage Breast Cancer
An artificial intelligence tool developed by Manisha Bahl, MD, and colleagues identifies patients with low-risk early-stage breast cancer who are appropriate candidates for active surveillance programs, thus helping the patients avoid unnecessary surgery or radiation.
-
Ultrasound-guided Cryoablation Offers Minimally Invasive Alternative for Treatment of Early-Stage Breast Cancer
Ultrasound-guided cryoablation offers a range of advantages over conventional approaches to treating breast cancer. In October 2023, Massachusetts General Hospital successfully introduced the technique into its clinical practice.
-
Case Report: Genomic Testing Identifies NTRK Fusions in Patient With Refractory Metastatic Breast Cancer
Arielle J. Medford MD, Aditya Bardia, MD, MPH and colleagues present the case of a woman with metastatic triple-negative breast cancer with secretory features who had disease progression on multiple lines of therapy but responded rapidly and dramatically to larotrectinib after two NTRK fusions were identified.
-
Novel Intraoperative Fluorescence Guidance Identifies Residual Tumor During Lumpectomy
Barbara Smith, MD, PhD, Michelle Gadd, MD and colleagues showed in a prospective, multicenter trial that a novel pegulicianine fluorescence-guided system, designed to allow intraoperative assessment of lumpectomy cavity margins and repeat shaves, facilitates removal of tumor left behind after standard surgery.
-
Editorial: Artificial Intelligence May Allow Reduced Use of Gadolinium-based Contrast Agents
Commenting on a German study, Manisha Bahl, MD, MPH, explains how AI can be applied to breast MRI scans acquired with low doses of gadolinium-based contrast agents (GBCAs) and predict the appearance of full-dose contrast-enhanced subtraction images, a potential way to reduce the dose and therefore toxicity of GBCAs.
-
Cell-Free DNA Assay Can Identify Microsatellite Instability–High Status in Advanced Breast Cancer
Neelima Vidula, MD, Dejan Juric, MD, Aditya Bardia, MD, MPH and colleagues from multiple centers in the U.S. have demonstrated that plasma-based genotyping ("liquid biopsy") can identify microsatellite instability–high status in patients with metastatic breast cancer.
Breast Cancer Contributors
-
Aditya Bardia, MD, MPH
Director of Precision Medicine, Center for Breast Cancer, Mass General Cancer Center, Founding Director, Molecular and Precision Medicine Metastatic Breast Cancer Clinic, Mass General Cancer Center, Assistant Professor in Medicine, Harvard Medical School
Recent Article
Case Report: Genomic Testing Identifies NTRK Fusions in Patient With Refractory Metastatic Breast Cancer
-
Constance D. Lehman, MD, PhD
Director, Division of Breast Imaging, Massachusetts General Hospital, Professor of Radiology, Harvard Medical School
Recent Article
Pragmatic Approach to Managing and Interpreting Breast Imaging After COVID-19 Vaccination
-
Douglas Scott Micalizzi, MD, PhD
Clinical Assistant, Medicine, Massachusetts General Hospital, Instructor, Medicine, Harvard Medical School
Recent Article
New Insight into Breast Cancer Metastasis—and the Potential for Preventing It
-
Manisha Bahl, MD, MPH
Radiologist, Breast Imaging Division, Department of Radiology, Massachusetts General Hospital, Associate Professor of Radiology, Harvard Medical School
Recent Article
Editorial: Artificial Intelligence May Allow Reduced Use of Gadolinium-based Contrast Agents
-
Richard Ebright, PhD
Postgraduate Research Fellow, Massachusetts General Hospital Cancer Center
Recent Article
New Insight into Breast Cancer Metastasis—and the Potential for Preventing It
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
